Amelanotic acral melanomas: clinicopathological, BRAF mutation, and KIT aberration analyses

J Am Acad Dermatol. 2013 Nov;69(5):700-707. doi: 10.1016/j.jaad.2013.06.035. Epub 2013 Aug 21.

Abstract

Background: Amelanotic acral melanoma (AAM) is very rare and difficult to diagnose both clinically and pathologically. Complete-type AAM shows no black to brown pigmentation in the lesion, whereas incomplete-type AAM shows focal or subtle pigmentation. AAM has been the subject of few investigations.

Objectives: We analyzed the clinicopathological features, BRAF mutations, and KIT aberrations in 35 Korean AAM cases.

Methods: We included 28 cases of complete-type and 7 cases of incomplete-type AAM.

Results: In all, 26 AAMs (45.7%) were located on the feet of patients, 21 of which (82.9%) showed ulceration. Sixteen cases developed in subungual areas. Nodular melanoma was the most common histopathological subtype (63.6%). The most frequent cell types affected were epithelioid and spindled. HMB-45 staining was strongly positive in 66.7% of AAMs; 4 (12.1%) were negative for HMB-45, and 3 of these were complete-type AAMs. Of 33 total patients, BRAF mutations were detected in 2 AAM cases, and KIT aberrations were present in 11 cases (33.3%). Four cases (12.1%), all of which were complete-type AAMs, had KIT mutations. KIT aberrations were weakly correlated with c-kit staining. Twenty patients were TNM stage I or II, and mean survival was 30.14 ± 4.54 months.

Limitations: The study is limited by the small number of patients.

Conclusion: Physicians should be aware of rare and hard-to-diagnose AAMs. We expect that tyrosine kinase inhibitors would be effective for KIT-mutated patients with complete-type AAMs.

Keywords: AAM; AJCC; American Joint Committee on Cancer; BRAF mutation; HMB-45; KIT mutation; PCR; acral melanoma; amelanotic acral melanoma; amelanotic melanoma; polymerase chain reaction; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Female
  • Humans
  • Male
  • Melanoma, Amelanotic / genetics*
  • Melanoma, Amelanotic / pathology*
  • Mutation*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Proto-Oncogene Proteins c-kit / genetics*

Substances

  • Proto-Oncogene Proteins c-kit
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf